A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma

Inclusion Criteria: * Diagnosis of Hodgkin's lymphoma failing or relapsing after first-line chemotherapy (MOPP/AVBD , MOPP/EBV/CAD and analogs are considered one line) * Age \>18 and \<65 years * Signed informed consent * If female, patient is either postmenopausal or surgically sterilized or willing to use an acceptable method of birth control * If male, patient agrees to use an acceptable barrier method for contraception * ECOG performance status \<2 * Platelet count \>100.000/mmc * Hemoglobin \>7.5 g/dL * Absolute neutrophil count (ANC) \>1.500/mmc * Serum calcium \<3.5 mmol/L (\<14 mg/dL) * AST/ALT: \<2.5 x the ULN * Total bilirubin: \<1.5 x the ULN Exclusion Criteria: * Previous treatment with velcade * Nitrosoureas within 6 weeks or any other chemotherapy within 3 weeks before enrollment * Immunotherapy or antibody therapy within 4 weeks before enrollment * Experimental drug or medical device within 4 weeks before start of treatment * Major surgery within 4 weeks before enrollment * History of allergic reaction attributable to compounds containing boron or mannitol or any of the drugs in the IGEV regimen * Peripheral neuropathy of NCI CTCAE Grade 2 or higher * Myocardial infarction within 6 months of enrollment or NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities * History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances including diabetes mellitus * Need for therapy with concomitant CYP 3A4 inhibitors or inducers * HIV-positive, if known * Hepatitis B surface antigen-positive or active hepatitis C infection, if known * Active systemic infection requiring treatment * If female, pregnancy or breast-feeding.